Ceres Ventures (OTCMKTS:CEVE) and RadNet (NASDAQ:RDNT) Head-To-Head Survey

Ceres Ventures (OTCMKTS:CEVE) and RadNet (NASDAQ:RDNT) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, analyst recommendations, institutional ownership, earnings and profitability.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Ceres Ventures and RadNet, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ceres Ventures	0	0	0	0	0.00
RadNet	0	0	3	3	3.50

RadNet has a consensus price target of $69.60, indicating a potential upside of 25.45%. Given RadNet’s stronger consensus rating and higher probable upside, analysts clearly believe RadNet is more favorable than Ceres Ventures.

Insider & Institutional Ownership

77.9% of RadNet shares are held by institutional investors. 0.1% of Ceres Ventures shares are held by insiders. Comparatively, 5.6% of RadNet shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

Ceres Ventures has a beta of 2.68, meaning that its share price is 168% more volatile than the S&P 500. Comparatively, RadNet has a beta of 1.41, meaning that its share price is 41% more volatile than the S&P 500.

Valuation & Earnings

This table compares Ceres Ventures and RadNet”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ceres Ventures	N/A	N/A	N/A	N/A	N/A
RadNet	$1.83 billion	2.28	$2.79 million	($0.43)	-129.02

RadNet has higher revenue and earnings than Ceres Ventures.

Profitability

This table compares Ceres Ventures and RadNet’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ceres Ventures	N/A	N/A	N/A
RadNet	-1.73%	1.41%	0.48%

Summary

RadNet beats Ceres Ventures on 9 of the 11 factors compared between the two stocks.

About Ceres Ventures

Ceres Ventures, Inc., a development stage company, focuses on the research, development, and commercialization of clean technologies for the remediation of polluted water, soil, and air. Its technologies include BluFlow Nanoparticles, a proprietary system for formulating, producing, and deploying customizable absorbent nanoparticles to specific functionality for contaminant/chemical removal and extraction of valuable elements and compounds from water based solutions; BluFlow Advanced Ultrafiltration Technology, an automated process to recover water from waste or impure streams; and BluFlow Treatment System a water and wastewater treatment solution, which incorporates the BluFlow Nanoparticles and the BluFlow Advanced Ultrafiltration Technology to remove target elements, compounds, and pollutants, as well as purify water that may be suitable for reuse. Ceres Ventures, Inc.'s products are used in water and wastewater treatment and purification, contaminated groundwater treatment, industrial wastewater treatment, and valuable elements and compounds extraction applications. The company was formerly known as PhytoMedical Technologies, Inc. and changed its name to Ceres Ventures, Inc. in November 2011. Ceres Ventures, Inc. was founded in 2010 and is based in New York, New York.

About RadNet

RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. The company operates in two segments: Imaging Centers and Artificial Intelligence. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems that distribute, display, store, and retrieve digital images; offers picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of breast, lung, and prostate images, as well as AI solutions for prostate cancer screening. RadNet, Inc. was founded in 1981 and is headquartered in Los Angeles, California.